From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006 by Bajcar, Jana M et al.
RESEARCH ARTICLE Open Access
From pharmaco-therapy to pharmaco-prevention:
trends in prescribing to older adults in Ontario,
Canada, 1997-2006
Jana M Bajcar
1,2,3,4,5, Li Wang
3, Rahim Moineddin
5,6, Jason X Nie
3,7, C Shawn Tracy
3,8, Ross EG Upshur
3,5,6,8,9*
Abstract
Background: The developed world is undergoing a demographic transition with greater numbers of older adults
and higher rates of chronic disease. Most elder care is now provided by primary care physicians, who prescribe the
majority of medications taken by these patients. Despite these significant trends, little is known about population-
level prescribing patterns to primary care patients aged 65+.
Methods: We conducted a population-based retrospective cohort study to examine 10-year prescribing trends
among family physicians providing care to patients aged 65+ in Ontario, Canada.
Results: Both crude number of prescription claims and prescription rates (i.e., claims per person) increased
dramatically over the 10-year study period. The greatest change was in prescribing patterns for females aged 85+.
Dramatic increases were observed in the prescribing of preventive medications, such as those to prevent
osteoporosis (+2,347%) and lipid-lowering agents (+697%). And lastly, the number of unique classes of medications
prescribed to older persons has increased, with the proportion of older patients prescribed more than 10 classes of
medications almost tripling during the study period.
Conclusions: Prescribing to older adults by family physicians increased substantially during the study period. This
raises important concerns regarding quality of care, patient safety, and cost sustainability. It is evident that further
research is urgently needed on the health outcomes (both beneficial and harmful) associated with these dramatic
increases in prescribing rates.
Background
The developed world is experiencing a demographic
transition evidenced by population aging. Individuals are
living longer and accumulating a greater burden of
chronic diseases and, as a consequence, are utilizing
healthcare services at greater rates [1,2]. These trends
are expected to increase further as the “baby-boom”
generation advances toward later life.
One of the standard interventions in chronic disease
management is prescription medication. Medications
were historically employed chiefly as treatments to alle-
viate symptoms; however, in the late 20
th and early 21
st
centuries, medications have been increasingly utilized as
preventive agents to modify and/or reduce health risks.
Most chronic disease management and medication
prescription occurs in primary care by family physicians.
Although data are available for overall medication use
for all age groups [3] and for specific medical condi-
tions, [4-6] little is known about population-level pre-
scribing patterns for family physicians providing care to
older adults. Therefore, we asked the following research
questions:
1. What are the trends of medication prescription to
individuals aged 65+ in thep r o v i n c eo fO n t a r i ob y
family physicians?
2. What are the most commonly prescribed classes
of medication, and have they changed over a 10-year
interval?
3. Do prescription claims per person vary by patient
age and sex?
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Study cohort
We conducted a population-based retrospective cohort
study to examine the prescribing trends of family physi-
cians providing care to older adults over a 10-year per-
iod (January 1, 1997 to December 31, 2006). All Ontario
residents aged 65+ who were eligible for universal public
health insurance and who made at least one Ontario
Drug Benefit (ODB) claim during the study period were
included in the analysis. Patients without valid Ontario
Health Insurance Plan (OHIP) numbers were excluded
from the analysis.
Data sources
Two administrative data sources were used to conduct
the analysis. The ODB database includes data on all pre-
scription medications dispensed to patients aged 65+ in
Ontario, Canada. The Institute for Clinical Evaluative
Sciences Physician Database (IPDB) is comprised of
information from three sources: the Corporate Provider
Database (CPDB), the Ontario Physician Human
Resource Data Centre (OPHRDC) database, and the
OHIP database of physician billings. The IPDB contains
information about all licensed physicians in Ontario,
including “physician specialty,” which was used to
extract family physicians for the present study. Physician
specialty has two elements: functional and certified.
While “certified” specialty derives from the physician’s
specialty certification, “functional” specialty is deter-
mined by the physician’s activity-based specialty, which
is assigned to each physician based on the combination
of OHIP services provided, patient age and sex, and
diagnoses that accounts for the highest proportion of
the physician’s total adjusted billings.
Analysis
All individual medication names were sorted using exist-
ing medication sub-classes classification from the ODB
database, after which medication sub-classes were
grouped into specific medication classes. The medica-
tion classes were created to capture the potential indica-
tion for the use of the medications by inferring from the
type of medications. Some medication classes were
more specific than others. The 12 medication classes
created through this process captured more than 80% of
all medications prescribed for the present study period.
All remaining classes - such as eye and ear preparations,
cancer agents, and dermatological preparations - were
collapsed into the “other classes” category.
Prescription claims were analyzed by patient age and
sex. Population data from Statistics Canada were used
in the calculation of age- and sex-specific rates. The
degree of change for each group and the proportion
that each group represents of the total was calculated
for 2006 and compared to 1997. All statistical analyses
were performed using SAS software version 9.1 (SAS
Institute, Inc., Cary, NC). This study was approved by
the Research Ethics Board at Sunnybrook Health
Sciences Centre.
Results
Over the 10-year period from 1997 to 2006, prescription
claims increased dramatically for older adults in
Ontario: from a total of 13,794,276 claims in 1997 to a
total of 43,348,670 claims in 2006. This represents a
214% increase over the study period, which far exceeds
the growth in the population of Ontario adults aged 65+
during this time period: from 1,384,739 in 1997 to
1,641,454 in 2006, an increase of 18.5%.
Table 1 shows the relative ranking of prescription
classes in both 1997 and 2006 and the percentage
change in rank order according to percentage increase
over the study period. In both 1997 and 2006, cardiovas-
cular medications were the most commonly prescribed
medications, followed by psychotropic and gastrointest-
inal medications. All medication classes increased over
the 10-year period, with several of the medication
c l a s s e si n c r e a s i n gb ym o r et h a n2 0 0 % .T h el o w e s t
increases were for primarily symptom-based therapies
(non-steroidal anti-inflammatory medications, antibio-
tics, asthma/chronic obstructive pulmonary disease
therapies, and corticosteroids.) The steepest increases
were for primarily preventive therapies: medications to
prevent osteoporosis increased 2,347%, and lipid-lower-
ing agents used to prevent cardiovascular disease
increased 697%. Preventive medications and medications
for chronic disease management have increased as a
relative percentage of claims, while more primarily
symptom-based medications such as analgesics, antibio-
tics, NSAIDS, COPD medications, and gastrointestinal
medications have declined.
Also presented in Table 1 are the per person prescrip-
tion claim rates for each of the unique classes of medi-
cation. (Compared to crude claims data, the use of
‘claims per person’ is advantageous as this measure con-
trols for any change in the population of interest during
the study period.) All classes of medication showed an
increase in average annual claims per person. For exam-
ple, for cardiovascular agents, in 1997 the average claims
per person was 3.2544, whereas in 2006 the average
claims per person was 9.4776, which represents an
increase of 191%.
Figure 1 presents the distribution of the number of
unique classes of medications prescribed to older adults
in Ontario. Data is presented for the years 1997 and
2006. Over this 10-year period, the proportion of older
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and the proportion of older adults taking one to three
classes of medications decreased by 17%. Conversely,
the proportion of older adults on four to nine classes of
medication increased by 34%. Over the same time per-
iod, the proportion of older adults who were prescribed
10 or more classes of medication increased by 188%.
Figure 2 presents the number of prescription claims
per person by gender. As illustrated, claims per person
were higher among females than males. In 1997, the
overall prescription claims rate for Ontarians aged 65+
was 10 claims per person (female = 11; male = 8); by
2006, the overall claims rate increased to 26 claims per
person (female = 31; male = 20).
Figure 3 presents the number of prescription claims
per person by age group for females and males, respec-
tively. For the 10-year study period, there was an annual
increase in the number of claims per person for both
sexes. The rate of increase in the number of claims per
person was greater for females than for males. This is
true for all age groups: in the 65-74 age group, claims
per person increased 107% for females and 101% for
males; in the 75-84 age group, claims per person
increased 170% for females and 132% for males; and,
finally, in the 85+ age group, claims per person
increased 286% for females and 210% for males.
Discussion
The present study indicates dramatic increases in both
absolute and per person prescription claims among
primary care patients aged 65+ in Ontario, Canada
over a 10-year time period. The year-over-year
increases are greatest among older females, particularly
those aged 85+. The data also demonstrate
Table 1 Prescription claims by medication class for primary care patients aged 65+ in Ontario, Canada
MEDICATION CLASS NUMBER OF CLAIMS PROPORTION OF TOTAL CLAIMS CLAIMS PER PERSON
1997 2006 Change 1997 2006 Change 1997 2006 Change
Osteoporosis 61,636 1,508,457 2,347% 0.38% 2.92% 668% 0.0445 0.919 1,965%
Lipid-lowering 445,390 3,549,066 697% 2.74% 6.88% 151% 0.3216 2.1621 572%
Thyroid replacements 484,499 1,724,859 256% 2.98% 3.34% 12% 0.3499 1.0508 200%
Psychotropics 1,899,995 6,716,502 254% 11.70% 13.02% 11% 1.3721 4.0918 198%
Cardiovascular 4,506,488 15,557,064 245% 27.75% 30.16% 9% 3.2544 9.4776 191%
Diabetes 686,009 2,341,826 241% 4.22% 4.54% 8% 0.4954 1.4267 188%
Gastrointestinal 1,764,359 5,326,708 202% 10.87% 10.33% -5% 1.2741 3.2451 155%
Narcotics/analgesics 638,156 1,350,001 112% 3.93% 2.62% -33% 0.4608 0.8224 78%
Corticosteroids 640,422 1,089,796 70% 3.94% 2.11% -46% 0.4625 0.6639 44%
NSAIDs 1,094,162 1,816,538 66% 6.74% 3.52% -48% 0.7902 1.1067 40%
Asthma/COPD 708,109 1,106,389 56% 4.36% 2.15% -51% 0.5114 0.674 32%
Antibiotics 865,051 1,261,464 46% 5.33% 2.45% -54% 0.6247 0.7685 23%
All other classes 2,619,665 7,685,790 193% 15.06% 15.96% 6% 1.8918 4.6823 148%
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Figure 1 Frequency distribution of number of unique medication classes for older adults aged 65+ in Ontario, Canada, 1997-2006.
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medications prescribed to older adults. Our data show
the most significant increases in prescriptions occur-
ring for risk factor management and chronic disease
prevention and declines in relative terms of medica-
tions for symptom management. The data suggest a
profound shift of clinical focus from treatment to pre-
ventive modalities in this population [7].
The increase in prescription claims cannot be
explained entirely by increase in population, as the pre-
scription claims per person is almost threefold higher
than population increases. The prescription increases
may be partially explained by greater reliance on clinical
practice guidelines, [8,9] particularly more aggressive
identification and management of risk factors for
chronic conditions such as cardiovascular disease and
osteoporosis. This trend towards increased use of pre-
ventive medications has resulted in a greater number of
medication classes per patient, which has resulted in a
shift in the profile of the typical elderly primary care
patient. Whereas the regimen for a typical elderly pri-
mary care patient consisted of fewer than five classes of
medications, now a greater proportion of these patients
are on more than five classes. Taken together, these
findings raise important questions concerning quality of
care, safety, and cost.
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Figure 2 Gender differences in prescription claims per person for older adults aged 65+ in Ontario, Canada, 1997-2006.
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Figure 3 Age differences in prescription claims per person for older adults aged 65+ in Ontario, Canada, 1997-2006.
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benefits associated with the steep increase in prescrip-
tions, particularly the increase in the number of classes
of medications prescribed and the steep increases in the
oldest age groups (i.e., 85+). There is increased use of
clinical guidelines to guide medication prescribing; how-
ever, there are few clinical trials that have included
elderly patients and so all claims for the effectiveness of
such therapies with elderly patients are extrapolations
from trials of younger patients [10]. As well, the rising
rates of prescribing speak to the increasing complexity
of clinical care. Increasing medication rates might
explain, at least in part, the observed increase in visits
to their family physician [1]. Increased medication pre-
scribing creates complex treatment regimens. For physi-
cians, this added complexity results in the need for
more intense monitoring and increased management of
side effects. For patients and their families, following
complex medication regimens is difficult and burden-
some; therefore, adherence rates are often low [11,12].
Taken together, then, the complexity involved with
complex medication regimens results in cases that can-
not be properly managed in conventional primary care
visits [13].
The dramatic increase in prescriptions also raises con-
cerns for patient safety and the potential for iatrogenic
harm, particularly as many older adults now take multi-
ple concomitant medications [14-16]. A number of
recent studies have raised potential concerns with
increased use of medications such as antipsychotic med-
ications in the older and vulnerable adults [17]. The
interactions of many of these medications are unknown,
but recent research has shown the possibility of many
harmful interactions, especially in older adults who have
physiologic changes that impact medication clearance
and pharmaco-dynamics [18]. There is a risk that
increasing medication use, even for appropriate indica-
tions, may initiate a “prescribing cascade” where a medi-
cation causes an adverse effect for which another
m e d i c a t i o nt h e ni sp r e s c r i b e d ,w h i c ht h e ni nt u r nc a n
cause another adverse effect for which another medica-
tion is prescribed [19]. Therefore, it is imperative that
future studies evaluate the harms and benefits of com-
plex medication regimens.
The increases in prescription claims per person docu-
mented in this study provide the basis for further
exploration of associated cost implications. With the
baby boom generation about to enter retirement age,
publicly-funded drug programs must assess their ability
to bear the costs associated with dramatic increases in
prescribing rates. A recent report published by the
Canadian Institutes of Health Information (CIHI) noted
that the top 10 medications prescribed for older adults
in six Canadian provinces account for 48% of all
medication expenditures on older adults [20]. It is
important to note, however, that this report did not
include data from Ontario, British Columbia, or Quebec
as prescription claims from these provinces are not sub-
mitted to the National Prescription Drug Utilization
Information System database that was used for this
report. Similar increases in use of prescription medica-
tions in the past decade have been observed in England.
In 1997, adults aged 60+ were prescribed 22.3 medica-
tions per year on average; by 2006, this had increased to
42.4 medications per year [21]. There is also evidence
demonstrating that nearly half of the total expenditures
on prescription medications are accounted for by 5% of
the population; nearly half of these high-cost users were
over the age of 65 [3].
The greatest strength of this study is its population
b a s e .W ew e r ea b l et oc a p t u r ea l lp r e s c r i p t i o nc l a i m s
g e n e r a t e db yf a m i l yp h y s i c i a n sf o ra l le l i g i b l eo l d e r
Ontarians in the study period. As noted above, the recent
CIHI report did not include data from Ontario, which is
Canada’s most populous province. A limitation is that we
do not have data for over-the-counter medications,
which can be numerous for older adults, [22,23] so our
data underestimate overall medication usage. Our data
do not reflect actual medication consumption by patients,
nor do our data reflect the actual number of prescrip-
t i o n st h a tw e r ew r i t t e n ,o n l yt h o s et h a tw e r eb r o u g h tt o
t h ep h a r m a c ya n dd i s p e n s e d .S i n c ep o o ra d h e r e n c eo f
medication regimens is common, including not bringing
a prescription to a pharmacy, the methodology used in
this study does not capture the actual medications pre-
scribed nor the actual amount consumed.
Conclusions
These data indicate dramatic increases in prescription
claims in the province of Ontario, Canada over a recent
10-year time span. These increases, particularly among
older females, cannot be explained by population
increase and are unlikely the result of increased disease
burden. The observed increases in prescribing rates,
especially in the number of unique classes of medica-
tions, have important implications for quality of care,
safety, and cost [24]. Given the growing concern regard-
ing polypharmacy, given the increasingly-complex medi-
cation regimens prescribed to older patients, and given
the absence of detailed knowledge of possible medica-
tion interactions, it is evident that further research is
urgently needed on the health outcomes (both beneficial
and harmful) associated with these dramatic increases in
prescribing rates.
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